Vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
Radiotherapy	I:C1522449
for	O
Localized	O
Prostate	O
Cancer	I:C0600139
to	O
Preserve	O
Erectile	O
Function	I:C0030847
:	O
A	O
Single	O
-	I:C0008976
arm	I:C0008976
Phase	I:C0008976
2	I:C0008976
Trial	I:C0008976
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
Radiotherapy	I:C1522449
for	O
Localized	B:C0392752
Prostate	O
Cancer	I:C0600139
to	O
Preserve	O
Erectile	O
Function	I:C0030847
:	O
A	O
Single	O
-	I:C0008976
arm	I:C0008976
Phase	I:C0008976
2	I:C0008976
Trial	I:C0008976
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
Radiotherapy	I:C1522449
for	O
Localized	O
Prostate	B:C0600139
Cancer	I:C0600139
to	O
Preserve	O
Erectile	O
Function	I:C0030847
:	O
A	O
Single	O
-	I:C0008976
arm	I:C0008976
Phase	I:C0008976
2	I:C0008976
Trial	I:C0008976
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
Radiotherapy	I:C1522449
for	O
Localized	O
Prostate	O
Cancer	I:C0600139
to	O
Preserve	O
Erectile	B:C0030847
Function	I:C0030847
:	O
A	O
Single	O
-	I:C0008976
arm	I:C0008976
Phase	I:C0008976
2	I:C0008976
Trial	I:C0008976
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
Radiotherapy	I:C1522449
for	O
Localized	O
Prostate	O
Cancer	I:C0600139
to	O
Preserve	O
Erectile	O
Function	I:C0030847
:	O
A	O
Single	B:C0008976
-	I:C0008976
arm	I:C0008976
Phase	I:C0008976
2	I:C0008976
Trial	I:C0008976
.	O

Erectile	B:C0242350
dysfunction	I:C0242350
remains	O
the	O
most	O
common	O
side	O
effect	I:C0879626
from	O
radical	O
treatment	I:C0194810
of	O
localized	O
prostate	O
cancer	I:C0600139
.	O

Erectile	O
dysfunction	I:C0242350
remains	O
the	O
most	O
common	O
side	B:C0879626
effect	I:C0879626
from	O
radical	O
treatment	I:C0194810
of	O
localized	O
prostate	O
cancer	I:C0600139
.	O

Erectile	O
dysfunction	I:C0242350
remains	O
the	O
most	O
common	O
side	O
effect	I:C0879626
from	O
radical	B:C0194810
treatment	I:C0194810
of	O
localized	O
prostate	O
cancer	I:C0600139
.	O

Erectile	O
dysfunction	I:C0242350
remains	O
the	O
most	O
common	O
side	O
effect	I:C0879626
from	O
radical	O
treatment	I:C0194810
of	O
localized	B:C0392752
prostate	O
cancer	I:C0600139
.	O

Erectile	O
dysfunction	I:C0242350
remains	O
the	O
most	O
common	O
side	O
effect	I:C0879626
from	O
radical	O
treatment	I:C0194810
of	O
localized	O
prostate	B:C0600139
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	B:C0002808
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	B:C1514120
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	B:C0194810
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	B:C0030847
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	B:C0475190
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	B:C0025266
with	O
localized	O
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	B:C0392752
prostate	O
cancer	I:C0600139
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve	O
-	I:C1514120
sparing	I:C1514120
radical	I:C1514120
prostatectomy	I:C1514120
(	O
radical	O
prostatectomy	I:C0194810
)	O
,	O
would	O
improve	O
erectile	O
function	I:C0030847
preservation	O
while	O
maintaining	O
tumor	O
control	I:C0475190
for	O
men	O
with	O
localized	O
prostate	B:C0600139
cancer	I:C0600139
.	O

To	O
determine	O
erectile	O
function	O
rates	O
after	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
.	O

Men	B:C0025266
with	O
localized	O
prostate	O
cancer	I:C0600139
were	O
enrolled	O
in	O
a	O
phase	O
2	I:C0008976
single	I:C0008976
-	I:C0008976
arm	I:C0008976
trial	I:C0008976
(	O
NCT02958787	O
)	O
at	O
a	O
single	O
academic	I:C0000872
center	I:C0000872
.	O

Men	O
with	O
localized	B:C0392752
prostate	O
cancer	I:C0600139
were	O
enrolled	O
in	O
a	O
phase	O
2	I:C0008976
single	I:C0008976
-	I:C0008976
arm	I:C0008976
trial	I:C0008976
(	O
NCT02958787	O
)	O
at	O
a	O
single	O
academic	I:C0000872
center	I:C0000872
.	O

Men	O
with	O
localized	O
prostate	B:C0600139
cancer	I:C0600139
were	O
enrolled	O
in	O
a	O
phase	O
2	I:C0008976
single	I:C0008976
-	I:C0008976
arm	I:C0008976
trial	I:C0008976
(	O
NCT02958787	O
)	O
at	O
a	O
single	O
academic	I:C0000872
center	I:C0000872
.	O

Men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
were	O
enrolled	O
in	O
a	O
phase	B:C0008976
2	I:C0008976
single	I:C0008976
-	I:C0008976
arm	I:C0008976
trial	I:C0008976
(	O
NCT02958787	O
)	O
at	O
a	O
single	O
academic	I:C0000872
center	I:C0000872
.	O

Men	O
with	O
localized	O
prostate	O
cancer	I:C0600139
were	O
enrolled	O
in	O
a	O
phase	O
2	I:C0008976
single	I:C0008976
-	I:C0008976
arm	I:C0008976
trial	I:C0008976
(	O
NCT02958787	O
)	O
at	O
a	O
single	B:C0000872
academic	I:C0000872
center	I:C0000872
.	O

Patients	O
received	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	O
and	O
MRI	O
-	O
angiogram	O
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	O
.	O

Patients	O
received	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	B:C0024485
and	O
MRI	O
-	O
angiogram	O
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	O
.	O

Patients	O
received	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	O
and	O
MRI	B:C0024485
-	O
angiogram	O
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	O
.	O

Patients	O
received	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	O
and	O
MRI	O
-	O
angiogram	B:C0002978
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	O
.	O

Patients	O
received	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	O
and	O
MRI	O
-	O
angiogram	O
to	O
delineate	O
and	O
avoid	O
the	O
erectile	B:C0030847
vasculature	O
.	O

Patients	O
received	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
utilizing	O
a	O
planning	O
MRI	O
and	O
MRI	O
-	O
angiogram	O
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	B:C3714653
.	O

Both	O
physician	B:C0031831
-	O
and	O
patient	O
-	O
reported	O
inventories	O
were	O
used	O
to	O
capture	O
erectile	O
function	I:C0030847
at	O
baseline	O
and	O
at	O
2	O
and	O
5	O
yr	O
after	O
treatment	O
.	O

Both	O
physician	O
-	O
and	O
patient	O
-	O
reported	O
inventories	O
were	O
used	O
to	O
capture	O
erectile	B:C0030847
function	I:C0030847
at	O
baseline	O
and	O
at	O
2	O
and	O
5	O
yr	O
after	O
treatment	O
.	O

Both	O
physician	O
-	O
and	O
patient	O
-	O
reported	O
inventories	O
were	O
used	O
to	O
capture	O
erectile	O
function	I:C0030847
at	O
baseline	O
and	O
at	O
2	O
and	O
5	O
yr	O
after	O
treatment	B:C0087111
.	O

Validated	B:C3161035
model	I:C3161035
-	O
based	O
comparisons	O
were	O
performed	O
to	O
compare	O
vessel	O
-	I:C1522449
sparing	I:C1522449
results	O
to	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
and	O
conventional	O
radiotherapy	I:C1522449
.	O

Validated	O
model	I:C3161035
-	O
based	O
comparisons	O
were	O
performed	O
to	O
compare	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
results	O
to	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
and	O
conventional	O
radiotherapy	I:C1522449
.	O

Validated	O
model	I:C3161035
-	O
based	O
comparisons	O
were	O
performed	O
to	O
compare	O
vessel	O
-	I:C1522449
sparing	I:C1522449
results	O
to	O
nerve	B:C1514120
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
and	O
conventional	O
radiotherapy	I:C1522449
.	O

Validated	O
model	I:C3161035
-	O
based	O
comparisons	O
were	O
performed	O
to	O
compare	O
vessel	O
-	I:C1522449
sparing	I:C1522449
results	O
to	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
and	O
conventional	B:C1522449
radiotherapy	I:C1522449
.	O

From	O
2001	O
to	O
2009	O
,	O
135	O
men	B:C0025266
underwent	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
.	O

From	O
2001	O
to	O
2009	O
,	O
135	O
men	O
underwent	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
.	O

After	O
a	O
planned	O
interim	O
analysis	B:C0936012
,	O
the	O
trial	O
was	O
stopped	O
after	O
meeting	O
the	O
primary	O
endpoint	O
.	O

After	O
a	O
planned	O
interim	O
analysis	O
,	O
the	O
trial	B:C0008976
was	O
stopped	O
after	O
meeting	O
the	O
primary	O
endpoint	O
.	O

The	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
was	O
8.7	O
yr	O
,	O
with	O
a	O
≥	O
94	O
%	O
response	O
rate	O
to	O
all	O
inventories	O
at	O
each	O
time	O
point	O
.	O

At	O
5	O
yr	O
,	O
88	O
%	O
of	O
patients	O
were	O
sexually	B:C0241028
active	I:C0241028
with	O
or	O
without	O
the	O
use	O
of	O
sexual	O
aids	O
.	O

The	O
2	O
-	O
yr	O
erectile	O
function	O
rates	O
were	O
significantly	O
improved	O
with	O
vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
(	O
78	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
71-85	O
%	O
)	O
compared	O
to	O
modeled	O
rates	O
for	O
convention	O
radiotherapy	I:C1522449
(	O
42	O
%	O
,	O
95	O
%	O
CI	O
38	O
-	O
45	O
%	O
;	O
p<0.001	O
)	O
or	O
nerve	O
-	I:C1514120
sparing	I:C1514120
prostatectomy	I:C1514120
(	O
24	O
%	O
,	O
95	O
%	O
CI	O
22	O
-	O
27	O
%	O
;	O
p<0.001	O
)	O
.	O

The	O
2	O
-	O
yr	O
erectile	O
function	O
rates	O
were	O
significantly	O
improved	O
with	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
(	O
78	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
71-85	O
%	O
)	O
compared	O
to	O
modeled	O
rates	O
for	O
convention	B:C1522449
radiotherapy	I:C1522449
(	O
42	O
%	O
,	O
95	O
%	O
CI	O
38	O
-	O
45	O
%	O
;	O
p<0.001	O
)	O
or	O
nerve	O
-	I:C1514120
sparing	I:C1514120
prostatectomy	I:C1514120
(	O
24	O
%	O
,	O
95	O
%	O
CI	O
22	O
-	O
27	O
%	O
;	O
p<0.001	O
)	O
.	O

The	O
2	O
-	O
yr	O
erectile	O
function	O
rates	O
were	O
significantly	O
improved	O
with	O
vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
(	O
78	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
71-85	O
%	O
)	O
compared	O
to	O
modeled	O
rates	O
for	O
convention	O
radiotherapy	I:C1522449
(	O
42	O
%	O
,	O
95	O
%	O
CI	O
38	O
-	O
45	O
%	O
;	O
p<0.001	O
)	O
or	O
nerve	B:C1514120
-	I:C1514120
sparing	I:C1514120
prostatectomy	I:C1514120
(	O
24	O
%	O
,	O
95	O
%	O
CI	O
22	O
-	O
27	O
%	O
;	O
p<0.001	O
)	O
.	O

At	O
2	O
yr	O
after	O
treatment	B:C0087111
,	O
87	O
%	O
of	O
baseline	O
-	O
potent	O
men	O
retained	O
erections	O
suitable	O
for	O
intercourse	O
.	O

At	O
2	O
yr	O
after	O
treatment	O
,	O
87	O
%	O
of	O
baseline	O
-	O
potent	O
men	B:C0025266
retained	O
erections	O
suitable	O
for	O
intercourse	O
.	O

At	O
2	O
yr	O
after	O
treatment	O
,	O
87	O
%	O
of	O
baseline	O
-	O
potent	O
men	O
retained	O
erections	B:C0030847
suitable	O
for	O
intercourse	O
.	O

At	O
2	O
yr	O
after	O
treatment	O
,	O
87	O
%	O
of	O
baseline	O
-	O
potent	O
men	O
retained	O
erections	O
suitable	O
for	O
intercourse	B:C0009253
.	O

The	O
5	O
-	O
and	O
10	O
-	O
yr	O
rates	O
of	O
biochemical	O
relapse	O
-	O
free	O
survival	O
were	O
99.3	O
%	O
and	O
89.9	O
%	O
,	O
and	O
at	O
5	O
yr	O
the	O
biochemical	O
failures	O
were	O
limited	O
to	O
the	O
National	B:C1513893
Comprehensive	I:C1513893
Cancer	I:C1513893
Network	I:C1513893
high	O
-	O
risk	O
group	O
.	O

Vessel	B:C1522449
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-	O
predicted	O
outcomes	O
following	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	O
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	O
control	I:C0475190
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	B:C0030847
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-	O
predicted	O
outcomes	O
following	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	O
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	O
control	I:C0475190
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	B:C3161035
-	O
predicted	O
outcomes	O
following	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	O
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	O
control	I:C0475190
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-	O
predicted	O
outcomes	O
following	O
nerve	B:C1514120
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	O
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	O
control	I:C0475190
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-	O
predicted	O
outcomes	O
following	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	B:C1522449
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	O
control	I:C0475190
.	O

Vessel	O
-	I:C1522449
sparing	I:C1522449
radiotherapy	I:C1522449
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	I:C0030847
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-	O
predicted	O
outcomes	O
following	O
nerve	O
-	I:C1514120
sparing	I:C1514120
RP	I:C1514120
or	O
conventional	O
radiotherapy	I:C1522449
,	O
with	O
maintenance	O
of	O
tumor	B:C0475190
control	I:C0475190
.	O

In	O
this	O
interim	O
analysis	B:C0936012
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	O
structures	I:C0458701
to	O
preserve	O
erectile	O
function	I:C0030847
after	O
prostate	O
cancer	I:C0600139
radiotherapy	O
.	O

In	O
this	O
interim	O
analysis	O
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	B:C0458701
structures	I:C0458701
to	O
preserve	O
erectile	O
function	I:C0030847
after	O
prostate	O
cancer	I:C0600139
radiotherapy	O
.	O

In	O
this	O
interim	O
analysis	O
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	O
structures	I:C0458701
to	O
preserve	O
erectile	B:C0030847
function	I:C0030847
after	O
prostate	O
cancer	I:C0600139
radiotherapy	O
.	O

In	O
this	O
interim	O
analysis	O
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	O
structures	I:C0458701
to	O
preserve	O
erectile	O
function	I:C0030847
after	O
prostate	B:C0600139
cancer	I:C0600139
radiotherapy	O
.	O

In	O
this	O
interim	O
analysis	O
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	O
structures	I:C0458701
to	O
preserve	O
erectile	O
function	I:C0030847
after	O
prostate	O
cancer	I:C0600139
radiotherapy	B:C1522449
.	O

We	O
found	O
that	O
almost	O
90	O
%	O
of	O
patients	O
at	O
5	O
yr	O
after	O
treatment	B:C0087111
remained	O
sexually	O
active	I:C0241028
,	O
significantly	O
higher	O
than	O
previous	O
studies	O
with	O
surgery	O
or	O
radiotherapy	O
.	O

We	O
found	O
that	O
almost	O
90	O
%	O
of	O
patients	O
at	O
5	O
yr	O
after	O
treatment	O
remained	O
sexually	B:C0241028
active	I:C0241028
,	O
significantly	O
higher	O
than	O
previous	O
studies	O
with	O
surgery	O
or	O
radiotherapy	O
.	O

We	O
found	O
that	O
almost	O
90	O
%	O
of	O
patients	O
at	O
5	O
yr	O
after	O
treatment	O
remained	O
sexually	O
active	I:C0241028
,	O
significantly	O
higher	O
than	O
previous	O
studies	O
with	O
surgery	B:C0543467
or	O
radiotherapy	O
.	O

We	O
found	O
that	O
almost	O
90	O
%	O
of	O
patients	O
at	O
5	O
yr	O
after	O
treatment	O
remained	O
sexually	O
active	I:C0241028
,	O
significantly	O
higher	O
than	O
previous	O
studies	O
with	O
surgery	O
or	O
radiotherapy	B:C1522449
.	O

